{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:03:19Z","timestamp":1792886599861,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acne vulgaris is a common chronic inflammatory skin disease with largely unmet treatment needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      This was a multi\u2010centre, randomized, double\u2010blind, placebo\u2010controlled, dose\u2010escalation Phase 2 trial (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link>\n                      ID: NCT05104125) to evaluate the safety, tolerability and efficacy of denifanstat, a first\u2010in\u2010class fatty acid synthase inhibitor, in patients with moderate\u2010to\u2010severe acne vulgaris. Denifanstat was administered orally at 25 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200945), 50 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200944), 75 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200945) mg or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200945) once daily after dinner for 12\u2009weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Denifanstat was generally well\u2010tolerated. Study drug\u2010related TEAEs were 48.9% (22\/45), 47.7% (21\/44), 62.2% (28\/45) and 48.9% (22\/45) in the denifanstat 25, 50 and 75\u2009mg and placebo groups, respectively. The most common TEAEs were dry eye, dry skin, urine protein positive, skin peeling and conjunctivitis (Grade 1 to 2). No serious drug\u2010related TEAEs occurred. At Week 12, denifanstat demonstrated significantly greater median reductions in total lesion counts versus placebo (25\u2009mg: \u221253.2% [Q1\u2013Q3: \u221262.5% to \u221237.6%]; 50\u2009mg: \u221261.3% [\u221278.2% to \u221229.1%]; 75\u2009mg: \u221253.1% [\u221262.4% to \u221239.2%] vs. placebo: \u221234.2% [\u221253.0% to \u221218.4%]; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The proportion of participants achieving a \u2265\u20092\u2010grade reduction in Investigator's Global Assessment (IGA) for denifanstat 25, 50 and 75\u2009mg and placebo was 31.1% (14\/45), 31.8% (14\/44), 22.2% (10\/45) and 15.6% (7\/45), respectively. The difference among the four groups was not significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.336).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Denifanstat 50\u2009mg once daily for 12\u2009weeks was generally well tolerated and showed potential to reduce total lesion counts in moderate\u2010to\u2010severe acne vulgaris. Larger and longer term studies are needed to confirm efficacy and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70119","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T19:04:42Z","timestamp":1762283082000},"page":"1238-1246","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Denifanstat for moderate\u2010to\u2010severe acne: A Phase 2, randomized, double\u2010blind, placebo\u2010controlled trial"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4140-8458","authenticated-orcid":false,"given":"Qinyi","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Dermatology Huashan Hospital, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rixin","family":"Chen","sequence":"additional","affiliation":[{"name":"The First People\u2019s Hospital of NanYang  Nanyang Henan Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[{"name":"Affiliated Hangzhou First People\u2019s Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai\u2019e","family":"Xu","sequence":"additional","affiliation":[{"name":"Hangzhou Third People\u2019s Hospital  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"He","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Kunming Medical University  Kunming Yunnan Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Ningbo No. 2 Hospital  Ningbo Zhejiang Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7159-879X","authenticated-orcid":false,"given":"Yan","family":"Lu","sequence":"additional","affiliation":[{"name":"1st Affiliated Hospital Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Second Xiangya Hospital of Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunfei","family":"Liu","sequence":"additional","affiliation":[{"name":"The Fourth Affiliated Hospital Zhejiang University School of Medicine  Yiwu City Zhejiang Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Feng","sequence":"additional","affiliation":[{"name":"ChengDu Second People\u2019s Hospital  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University, Third Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunyi","family":"Dai","sequence":"additional","affiliation":[{"name":"Wuxi No. 2 People\u2019s Hospital  Wuxi Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-9336","authenticated-orcid":false,"given":"Ying","family":"Gao","sequence":"additional","affiliation":[{"name":"The Central Hospital of WuHan  Wuhan Hubei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemei","family":"Yan","sequence":"additional","affiliation":[{"name":"Ascletis BioScience Co., Ltd.  Hangzhou Zhejiang Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzi J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Ascletis BioScience Co., Ltd.  Hangzhou Zhejiang Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-3962","authenticated-orcid":false,"given":"Leihong","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Huashan Hospital, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13462"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.045"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19477"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12298"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15754"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1029818"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau8465"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00367-2"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.02.021"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.12.017"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19459-z"},{"key":"e_1_2_12_13_1","article-title":"Fatty acid synthase inhibitor TVB\u20103664 reduces collagen accumulation in bleomycin\u2010induced murine skin fibrosis and reverses multiple components of diet\u2010induced and biopsy\u2010confirmed nonalcoholic steatohepatitis in mice treated with or without co\u2010administered pirfenidone","volume":"66","author":"Duke G","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_12_14_1","first-page":"1045A","article-title":"Pharmacologic inhibition of FASN reverses diet\u2010induced steatohepatitis in mice and inhibits lipogenesis in humans","volume":"66","author":"Parks EJ","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100797"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2807"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.07.025"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31000"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30460-9"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.069"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0178-4"},{"issue":"9","key":"e_1_2_12_22_1","first-page":"987","article-title":"Once\u2010daily Oral Sarecycline 1.5 mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double\u2010blind clinical trials","volume":"17","author":"Moore A","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"e_1_2_12_23_1","article-title":"Oral isotretinoin for acne","volume":"11","author":"Costa CS","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12010089"},{"key":"e_1_2_12_25_1","unstructured":"US Food and Drug Administration.Guidance for Industry on Acne Vulgaris: Developing Drugs for Treatment [Internet].2005[cited 2025 Feb 19]. Available from:https:\/\/www.regulations.gov\/document\/FDA\u20102005\u2010D\u20100461\u20100003"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00246-2"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70119","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70119","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:40:34Z","timestamp":1782484834000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/jdv.70119"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70119","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"2024-12-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}